IXJ
iShares Global Healthcare ETF · PSE
- Category Health Care
- Expense Ratio 0.42%
- Listing Date Nov 16, 2001
- Volume 134,020.0
- Market Cap (AUM) $3,649.48M
Performance
-2.96%
1W
-2.71%
1M
-13.03%
3M
-6.57%
6M
+0.44%
YTD
+3.34%
1Y
Top Holdings
-
Name
Symbol%Assets
- Eli Lilly and CompanyLLY9.33%
- UnitedHealth Group IncorporatedUNH5.99%
- Novo Nordisk A/S Class BNOVO.B5.98%
- Johnson & JohnsonJNJ4.50%
- Merck & Co., Inc.MRK4.27%
- AbbVie, Inc.ABBV3.96%
- AstraZeneca PLCAZN3.24%
- Thermo Fisher Scientific Inc.TMO2.91%
- Novartis AGNOVN2.88%
- Roche Holding Ltd Dividend Right Cert.ROG2.56%
Technical Analysis of IXJ 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2021-06-23 00:45
Medical Device ETF Debuts(Yahoo Finance)
- 2019-11-03 22:20
Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks(Yahoo Finance)
- 2019-08-06 03:45
- 2019-06-11 20:28
Traders Look to Buy Global Health Care Stocks(Investopedia)
- 2018-08-09 00:45
Investors Flocked to Healthcare ETFs in July(Yahoo Finance)
- 2018-08-01 22:47
5 Strong Healthcare ETFs to Buy(Yahoo Finance)
- 2018-03-29 04:30
BlackRock Announces Share Split for Four iShares ETFs(Yahoo Finance)
- 2018-01-24 20:38
Analysts Estimates for Pfizers 4Q17 Earnings(Marketrealist)
- 2018-01-18 04:30
Merck & Co.s Business Segments and Performance in 3Q17(Marketrealist)
- 2018-01-08 21:48
7 Best Healthcare ETFs for 2018(Yahoo Finance)
- 2017-10-02 01:27
9 Million American Children Lost Funding For Their Insurance(Yahoo Finance)
- 2017-09-11 21:06
- 2017-09-10 20:36
Whats Gilead Sciences Valuation?(Marketrealist)
- 2017-09-04 21:07
Performance of AstraZenecas CVMD Segment in 2Q17(Marketrealist)
- 2017-08-29 03:05
Bristol-Myers Squibbs Revenues in 2Q17(Marketrealist)
- 2017-08-22 21:07
Inside Incytes Jakafi Performance in 2Q17(Marketrealist)
- 2017-07-26 03:09
AstraZenecas 2Q17 Earnings: Analysts Estimates(Marketrealist)
- 2017-07-24 19:37
Major Developments for Johnson and Johnson(Marketrealist)
- 2017-07-17 22:37
Analyst Ratings and Recommendations for Novartis Post 2Q17(Marketrealist)
- 2017-07-16 22:37
Inside Allergans International Business(Marketrealist)
- 2017-07-10 19:37
How Celgene Stock Performed in 2Q17(Marketrealist)
- 2017-07-04 19:37
Johnson & Johnsons Medical Devices Business in 1Q17(Marketrealist)
- 2017-07-03 22:36
Performance of Mercks Diabetes Drugs in 1Q17(Marketrealist)
- 2017-06-27 21:06
Pfizers Geographical Performance in 1Q17(Marketrealist)
- 2017-06-21 19:36
Changes in Bristol-Myers Squibbs Profitability 1Q17(Marketrealist)
- 2017-06-04 22:36
Performance of Elanco in 1Q17(Marketrealist)
- 2017-05-30 19:36
- 2017-05-30 05:05
Johnson & Johnsons Business Segments in 1Q17(Marketrealist)
- 2017-05-29 02:05
AstraZenecas Segment-by-Segment Performance in 1Q17(Marketrealist)
- 2017-05-24 21:06
Performance of Mercks Animal Health Segment in 1Q17(Marketrealist)
- 2017-05-07 23:26
Allergans 1Q17 Earnings: Analysts Estimates(Marketrealist)
- 2017-05-05 05:36
Pfizers Geographical Performance in 1Q17(Marketrealist)
- 2017-04-25 21:07
GlaxoSmithKlines 1Q17 Estimates: Consumer Healthcare(Marketrealist)
- 2017-04-25 04:28
What Analysts Expect of Bristol-Myers Squibbs 1Q17 Earnings(Marketrealist)
- 2017-04-23 19:38
Novartiss 1Q17 Estimates for Sandoz(Marketrealist)
- 2017-04-13 03:05
Johnson & Johnsons Revenue Estimates: Expect Growth!(Marketrealist)
- 2017-04-09 21:06
Examining Gilead Sciences 1Q17 Performance(Marketrealist)
- 2017-04-07 01:35
Assessing Johnson & Johnsons 1Q17 Performance(Marketrealist)
- 2017-04-04 19:36
Must-Know Corporate and Pipeline Developments for Pfizer(Marketrealist)
- 2017-04-02 19:36
How Eli Lillys New Products Performed in 2016(Marketrealist)
Page 1 of 3
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.